New drug combo aims to wipe out leukemia cells in High-Risk patients
NCT ID NCT06253637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding daratumumab, an antibody that targets a protein on leukemia cells, to standard chemotherapy can clear all signs of cancer in adults with very high-risk T-cell acute lymphoblastic leukemia (T-ALL). About 31 patients aged 18-65 will receive the combination during their first round of treatment. The main goal is to see if more patients become MRD-negative (no detectable leukemia cells) after one cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab (a monoclonal antibody that targets CD38 on cancer cells) plus chemotherapy
What this could lead to
If successful, this could improve the chance of eliminating all detectable leukemia cells after initial treatment, potentially leading to better long-term outcomes for patients with very high-risk T-ALL.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply broadly. Daratumumab can cause infusion reactions and increase infection risk. The added benefit over standard chemo alone is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-LYMPHOCYTIC LEUKEMIA, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ematologia AOU Careggi
Florence, Italy
-
Ematologia AOU Policlinico Umberto I
Roma, Italy
-
Ematologia P.O. Vito Fazzi - Lecce
Lecce, Italy